Results of ledipasvir/sofosbuvir treatment on with HCV genotype 1b infection
- VernacularTitle:Хепатитын Cвирүсийн 1в генотиптэй өвчтөнүүдэд ледипасвир/ софосбувирэмийн эмчилгээний үр нөлөөг судлах нь
- Author:
Tuwshinbayar N
1
;
Baigal R
;
Gegeebadrakh B
Author Information
1. Second General Hospital
- Publication Type:Journal Article
- Keywords:
HCV genotype 1b;
ledipasvir/sofosbuvir(Harvoni);
sustained response (SVR);
recurrence
- From:Mongolian Medical Sciences
2016;178(4):29-33
- CountryMongolia
- Language:Mongolian
-
Abstract:
IntroductionGenotype 1 infection has been historically difficult to treat, but multiple recent studies have showntreatment results greater than high in these genotype 1b patients using well-tolerated, all-oral regimensconsisting of new direct-acting antiviral agents.GoalPurpose of the study was to define the effects of ledipasvir/sofosbuvir treatment on patients with HCVgenotype 1b infection.Materials and MethodsIn this study we enrolled 2 treatment-naive and 66 treatment-experienced, totally 68 patients who tookledipasvir/sofosbuvir during the period from January 2016 to March 2016. We used randomly selectedand double-blinded method in our clinical research. The descriptive and non-parametrical statisticaltests were conducted using SPSS Statistics 20.0.ResultsThe SVR12 and SVR24 rates were greater than 95% and no differences were observed in treatmentnaiveversus treatment-experienced patients.ConclusionTheSVR12 rates were found in 98.6% while the SVR24 was in 97.1% of 68 patients. Only 2.9% of thetotal cases were appeared relapse of HCV infection. These findings indicated needs of further studieson long-term effects of ledipasvir/sofosbuvir.
